In This Section      
 

Search Results

Title:
BR003 A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Protocol Number:
NCTNNBR003
Phase:
Phase III
Physician:
Deborah Armstrong
Sites:
Sibley Memorial Hospital
Johns Hopkins Kimmel Cancer Center in Baltimore
Purpose:
The purpose of this study is to compare the good and bad effects of the chemotherapy drug, carboplatin, given with the usual chemotherapy drugs after surgery, compared to the usual chemotherapy drugs given without carboplatin.
Eligibility:
Generally healthy adult females or males with ER, PR, and HER2 negative breast cancer who have undergone surgery may be eligible to participate.
Treatment:
Eligible participants will receive usual chemotherapy of doxorubicin and cyclophosphamide for 4 cycles followed by weekly paclitaxel for 12 doses. Half the participants will be randomized, like the flip of a coin, to also receive carboplatin once every 3 weeks while receiving weekly paclitaxel. All participants will be followed for up to 10 years.
Population:
Adult
Last Update
03/05/2019 05:03 AM